Parmentier S P, Rosenkranz E, Schirutschke H, Opgenoorth M, Quick C, Hoelig K, Rosner A, Hohenstein B, Hugo C, Passauer J
University Hospital Carl-Gustav-Carus, Department of Medicine III, Division of Nephrology, Germany.
Department of Medicine I, Division of Transfusion Medicine, Dresden, Germany.
Atheroscler Suppl. 2017 Nov;30:253-256. doi: 10.1016/j.atherosclerosissup.2017.05.017. Epub 2017 Jun 1.
ABO incompatible (ABOi) organ transplantation requires pre-transplant reduction of the recipient's IgG and IgM isoagglutinin titer against the donor to prevent hyperacute rejection. Over the past four years we primarily used unspecific IgG immunoadsorption (IA) for this purpose and combined this selectively with membrane filtration (IAc) to reduce IgM isoagglutinines. In patients with an initial IgG titer against donor below 1:64, plasma exchange (PE) was initiated. In this retrospective analysis covering January 2012 to August 2015 we compared how efficiently IgG and IgM isoagglutinines in a total of 22 ABOi kidney transplant recipients were reduced by either IA (n = 75 sessions), IAc (n = 14 sessions) or PE (n = 40 sessions). Median pre-treatment IgG isoagglutinin titers were 32 (4-4096) while IgM titers were 16 (1-256) respectively. Mean IgG reduction by either treatment modality was 1.3 ± 0.9 (IA), 1.8 ± 1.0 (IAc) and 2.6 ± 1.3 (PE) titer steps per session (p < 0.001 IA vs. PE; p < 0.04 PE vs. IAc). Mean IgM reduction was 0.6 ± 0.6 (IA), 1.8 ± 0.8 (IAc) and 2.4 ± 1.9 (PE) titer steps (p < 0.001 for both IA vs. PE and IA vs. IAc). Our data indicate that PE efficiently removed IgG- and IgM isoagglutinines. By processing only half the plasma volume per treatment PE was twice as effective as IA in terms of IgG-type isoagglutinin removal in our patient group. This is best explained by the presence of soluble AB0 antigens in the FFP used as plasma replacement. These advantages in efficacy have to be weighed against the potential hazards of PE. Combination of IA and plasma filtration effectively removes IgM-type and even enhances net IgG-type isoagglutinin elimination compared to IA alone. When trying to avoid PE, combined application of IA and IAc is a possible and effective way to reduce isoagglutinin titers before ABOi transplantation.
ABO血型不相容(ABOi)器官移植需要在移植前降低受者针对供者的IgG和IgM同种凝集素滴度,以防止超急性排斥反应。在过去四年中,我们主要使用非特异性IgG免疫吸附(IA)来达到这一目的,并选择性地将其与膜过滤(IAc)相结合以降低IgM同种凝集素。对于初始针对供者的IgG滴度低于1:64的患者,启动血浆置换(PE)。在这项涵盖2012年1月至2015年8月的回顾性分析中,我们比较了IA(n = 75次治疗)、IAc(n = 14次治疗)或PE(n = 40次治疗)对总共22例ABOi肾移植受者的IgG和IgM同种凝集素的降低效率。治疗前IgG同种凝集素滴度中位数为32(4 - 4096),而IgM滴度中位数分别为16(1 - 256)。每种治疗方式每次治疗使IgG降低的平均滴度为1.3±0.9(IA)、1.8±1.0(IAc)和2.6±1.3(PE)个滴度级别(IA与PE相比,p < 0.001;PE与IAc相比,p < 0.04)。使IgM降低的平均滴度为0.6±0.6(IA)、1.8±0.8(IAc)和2.4±